Deals this week: Takeda Pharma, Mesoblast Limited, Aslan Pharmaceuticals

7 July 2016 (Last Updated July 7th, 2016 18:30)

Takeda Pharmaceutical Company Limited has signed a definitive agreement with Altos Therapeutics LLC.

Takeda Pahrmaceuticals

Takeda Pharmaceutical Company Limited has signed a definitive agreement with Altos Therapeutics LLC.

Acroding to the agreement, the two companies will further develop ATC-1906, an Altos Therapeutics proprietary compound, to provide treatment to the patients suffering from gastroparesis and its symptoms.

Mesoblast Limited has announced that it will raise funds amounting to $44.65m through the private placement of its shares. The placement will be subscribed to by Kentgrove Capital.

The company plans to invest the funds to meet its additional funding requirements for the next three years.

Aslan Pharmaceuticals has raised gross proceeds of $23m in a venture financing round.

The company plans to use the funds for clinical development of its products in the pipeline for treating highly-prevalent tumour types in Asia.

"The company plans to use the funds for clinical development of its products in the pipeline for treating highly-prevalent tumour types in Asia."

Nantong jinghua Pharmaceuticals plans to offer a private placement of its share to raise up to $120.4m.

The company plans to use the proceeds to acquire Alpha Pharma.

Pharmaceutical product manufacturer Huons Global has announced a public offering of its 4,959,779 common stock shares.

The company plans to raise funds amounting to $250m from the offering, which is expected to be completed by 10 August 2016.


Image: Takeda Pharmaceutical Company Limited has signed a definitive agreement with Altos Therapeutics LLC. Photo : Courtesy of Lombroso.